Evidence map›Paper›PMID 41275414›Full record

ArticleCancer medicine2025

Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma.

Susanna Tokola, Katja Marin, Milla E L Kuusisto, Hanne Kuitunen, Marjukka Pollari, Sirkku Jyrkkiö, Minna Suominen, Kristiina Vuolukka, Minna Harmanen, Kaisa Sunela and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Susanna TokolaDepartment of Radiotherapy and Oncology, Oulu University Hospital, Oulu, Finland.
Katja MarinCancer Center, Kuopio University Hospital, Kuopio, Finland.
Milla E L KuusistoDepartment of Internal Medicine, Länsi-Pohja Central Hospital, Kemi, the Wellbeing County of Lappland, Kemi, Finland.
Hanne KuitunenDepartment of Radiotherapy and Oncology, Oulu University Hospital, Oulu, Finland.
Marjukka PollariDepartment of Oncology, Tampere University Hospital, TAYS Cancer Center, Tampere, Finland.
Sirkku JyrkkiöThe Wellbeing Services County of Southwest Finland, Turku University Hospital, Turku, Finland.
Minna SuominenNorth Karelia Central Hospital, Cancer Center, Joensuu, Finland.
Kristiina VuolukkaCancer Center, Kuopio University Hospital, Kuopio, Finland.
Minna HarmanenUniversity of Eastern Finland, Kuopio, Finland.
Kaisa SunelaFinnish Medicines Agency, Tampere, Finland.
Aino RönkäCancer Center, Kuopio University Hospital, Kuopio, Finland.
Tuomas SelanderCancer Center, Kuopio University Hospital, Kuopio, Finland.
Annikki Aromaa-HäyhäCancer Center, Kuopio University Hospital, Kuopio, Finland.
Stella YlhäinenUniversity of Eastern Finland, Kuopio, Finland.
Tuula KlaavuniemiUniversity of Eastern Finland, Kuopio, Finland.
Anna HakalahtiDepartment of Radiotherapy and Oncology, Oulu University Hospital, Oulu, Finland.
Outi KuittinenCancer Center, Kuopio University Hospital, Kuopio, Finland.ORCID https://orcid.org/0000-0001-9969-0053

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with often a high Ki-67 proliferation index. Prognosis is associated with lymphoma stage, lactate dehydrogenase level, and metabolic tumor volume. Thus, intuitively, time from symptom onset to diagnosis would be assumed to be essential for treatment outcome, but existing literature is conflicting. MATERIALS AND

methodsThis prospective study evaluated diagnostic pathways and their impact on treatment outcomes in 160 patients with DLBCL.

resultsThe mean time from symptom onset to treatment initiation (TST) was 146 days. Mean patient-associated delay from the onset of symptoms to the first healthcare contact was 54 days; mean time from symptoms to biopsy was 130 days; and from biopsy to treatment initiation was 19 days. Prolonged time from symptom onset to treatment (TST) > 3 months was associated with a higher International Prognostic Index (IPI) score, whereas prolonged time from biopsy to treatment initiation (TBT) > 2 weeks was associated with better performance status and a lower IPI score. Prolonged time from symptom onset to treatment initiation was not associated with progression-free survival (PFS). Prolonged time from symptom onset to diagnostic biopsy > 7 weeks implied inferior progression free survival in the whole study cohort (2 year PFS 89% vs. 74%, p = 0.012), as well as among patients with highly proliferating tumors with Ki67 > 70% (2 year PFS 93% vs. 63%, p < 0.001). Longer time from biopsy to treatment initiation (TBT) > 2 weeks implied better progression-free survival (PFS) in patients with low proliferating tumors (2 year progression-free survival (PFS) 25% vs. 87%, p = 0.032), respectively.

Indexed as

Lymphoma, Large B-Cell, DiffuseTime-to-TreatmentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiopsyFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalProspective StudiesTime FactorsYoung Adultdiagnostic pathwaysdiffuse large B‐cell lymphomainternational prognostic index (IPI)progression‐free survivalproliferating tumors

Identifiers

PMID41275414
PMCPMC12640614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.